Rapid Acting Insulin Market Share, Growth, Trends and Forecast 2022–2032

Rapid Acting Insulin Market Size- By Product, By Indication, By Distribution Channel- Regional Outlook, Competitive Strategies and Segment Forecasts to 2032

Published: Nov 2022 Base Year: 2021 Report ID: PHAR2210
Available Format: Historical Data: 2019 - 2020 Number of Pages: 1 - 243
Category : Pharmaceutical
Global Rapid Acting Insulin Market Overview:

According to SPER Market Research, the Rapid Acting Insulin Market is estimated to reach USD 11.85 billion by 2032 with a CAGR of 4.90%. 

Rapid acting insulin is a drug that diabetic individuals use to manage their blood sugar levels. It can be inhaled or given intravenously via an insulin pump, prefilled pen, syringe, or other devices. It is given before meals and snacks to lower abnormally high blood sugar levels and boost the amount of bolus insulin. Currently, persons who are unable to reach their postprandial glycemic goals with existing bolus insulins are thought to benefit from new insulin formulations including innovative ultra-fast-acting insulins that improve absorption.



Another reason driving the need for rapid acting insulins throughout the world is the rising prevalence of type-1 diabetes as a result of exposure to viruses and other environmental causes, poor vitamin D levels, and other environmental variables. This is also explained by the rise in neonatal jaundice cases in infants and the advancement of diagnostic tools. Additionally, the growing global elderly population is promoting market expansion since the risk of having diabetes rises with age. Leading market competitors are also producing ready-to-use kits of rapid acting insulin that are quick to administer, offered in vials and pens, and that improve glycemic control in both adults and children. These firms are also concentrating on mergers and acquisitions (M&A), which is projected to aid in the creation of new product versions for the next generation.

Increased investment in research and development (R&D) for human recombinant insulin is anticipated to drive the demand for insulin used in the management of diabetes, thereby boosting the market's growth. The global market for rapid acting insulin is primarily driven by the rise in the prevalence of diabetes on a global scale. Furthermore, because overweight or obese, an unhealthy diet, and physical inactivity, account for nearly 80% of the rise in the incidence of diabetes, sedentary and unhealthy lifestyles double the risk of developing the disease. However, the industry's expansion may be hampered by consumers' hesitation to use quick acting insulin because of adverse effects including hypoglycemia. On the other hand, emerging nations are predicted to provide attractive development prospects for the market for quick acting insulin because of their unexplored markets and undiagnosed population.



Impact of COVID-19 on the Global Rapid Acting Insulin Market  
The COVID-19 epidemic, which originated in Wuhan, China, has now spread far over the world. The epidemic is being dealt with by almost all countries. In addition, due to the lockdown scenario imposed by the governments of several nations, the majority of markets have seen a decline. However, it is anticipated that the COVID-19 epidemic would help open up new development potential for businesses involved in the treatment and management of chronic illnesses. Diabetes increases the risk of significant COVID-19 problems, according to a 2020 article by the American Diabetes Association.

Additionally, having diabetes together with heart disease or other issues raises the risk of developing significant COVID-19 illness since many illnesses impair a patient's ability to fight the infection. This aided important actors in adopting a variety of tactics to capture the largest possible proportion of the COVID-19 epidemic. Patients with coronavirus illness (COVID-19) may have an increase in mortality and severity due to diabetes mellitus (DM) and poorly managed blood sugar. This is one of the primary drivers behind the demand for fast-acting insulins to track blood glucose levels.

Scope of the Report:
 Report Metric Details
 Market size available for years 2019-2032
 Base year considered 2021
 Forecast period 2022-2032
 Segments coveredBy Product, By Indication, By Distribution Channel
 Geographies coveredNorth America, Europe, Asia Pacific, Latin America, Middle East and Africa
 Companies CoveredAdocia, Biocon Limited, Eli Lilly, Gan & Lee Pharmaceuticals Co. Ltd., Geropharm, MannKind Corporation, Merck & Co. Inc., Novo Nordisk A/S, Sanofi S.A., Wockhardt Ltd.
Global Rapid Acting Insulin Market Segmentation:

By Product: Based on the Product, Global Rapid Acting Insulin Market is segmented as; Lispro Insulin, Aspart Insulin, Glulisine Insulin.

By Indication: Based on the Indication, Global Rapid Acting Insulin Market is segmented as; Type 1 Diabetes and Type 2 Diabetes.

By Distribution Channel: 
Based on the Distribution Channel, Global Rapid Acting Insulin Market is segmented as; 
 Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Stores.

By Region: The region's rapid acting insulin market was primarily driven by North America and it is predicted that the region would continue to dominate the market as a result of rising diabetes occurrences and an aging population. On the other hand, Asia-Pacific is anticipated to see the greatest growth in the market for quick acting insulin in the coming years due to the spread of obesity and westernised living habits. Over the course of the projection, this is anticipated to drive up demand for quick acting insulin.

1. Introduction
1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology
2.1 Research data source
2.1.1 Secondary data
2.1.2 Primary data
2.1.3 SPER’s internal database
2.1.4 Premium insight from KOL’s
2.2 Market size estimation
2.2.1 Top-down and Bottom-up approach
2.3 Data triangulation

3. Executive Summary

4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges 
4.2. COVID-19 Impacts of the Global Rapid Acting Insulin Market 

5. Market variables and outlook
5.1. SWOT analysis 
5.1.1 Strengths 
5.1.2 Weaknesses 
5.1.3 Opportunities
5.1.4 Threats
5.2. PESTEL analysis 
5.2.1 Political landscape
5.2.2 Economic landscape
5.2.3 Social landscape 
5.2.4 Technological landscape 
5.2.5 Environmental landscape 
5.2.6 Legal landscape 
5.3. PORTER’S five forces analysis 
5.3.1 Bargaining power of suppliers 
5.3.2 Bargaining power of Buyers 
5.3.3 Threat of Substitute 
5.3.4 Threat of new entrant 
5.3.5 Competitive rivalry
5.4. Heat map analysis

6. Global Rapid Acting Insulin Market, By Product, 2019-2032 (USD Million)
6.1 Lispro Insulin
6.2 Aspart Insulin
6.3 Glulisine Insulin

7. Global Rapid Acting Insulin Market, By Indication, 2019-2032 (USD Million)
7.1 Type 1 Diabetes
7.2 Type 2 Diabetes

8. Global Rapid Acting Insulin Market, By Distribution Channel, 2019-2032 (USD Million)
8.1 Hospital Pharmacies
8.2 Drug Stores and Retail Pharmacies
8.3 Online Stores

9. Global Rapid Acting Insulin Market, By Region, 2019-2032 (USD Million)
9.1 North America
9.1.1 United States
9.1.2 Canada
9.1.3 Mexico
9.2 Europe
9.2.1 Germany
9.2.2 United Kingdom
9.2.3 France
9.2.4 Italy
9.2.5 Spain
9.2.6 Rest of Europe
9.3 Asia-Pacific
9.3.1 China
9.3.2 Japan
9.3.3 India
9.3.4 Australia
9.3.5 South Korea
9.3.6 Rest of Asia-Pacific
9.4 South America
9.4.1 Brazil
9.4.2 Argentina
9.4.3 Rest of South America
9.5 Middle East & Africa
9.5.1 Kingdom of Saudi Arabia 
9.5.2 United Arab Emirates
9.5.3 Rest of Middle East & Africa

10. Company Profiles
10.1 Adocia
10.1.1 Company details 
10.1.2 Financial outlook
10.1.3 Product summary 
10.1.4 Recent developments

10.2 Biocon Limited
10.2.1 Company details 
10.2.2 Financial outlook
10.2.3 Product summary 
10.2.4 Recent developments

10.3 Eli Lilly
10.3.1 Company details 
10.3.2 Financial outlook
10.3.3 Product summary 
10.3.4 Recent developments

10.4 Gan & Lee Pharmaceuticals Co. Ltd.
10.4.1 Company details 
10.4.2 Financial outlook
10.4.3 Product summary 
10.4.4 Recent developments

10.5 Geropharm
10.5.1 Company details 
10.5.2 Financial outlook
10.5.3 Product summary 
10.5.4 Recent developments

10.6 MannKind Corporation
10.6.1 Company details 
10.6.2 Financial outlook
10.6.3 Product summary 
10.6.4 Recent developments

10.7 Merck & Co. Inc.
10.7.1 Company details 
10.7.2 Financial outlook
10.7.3 Product summary 
10.7.4 Recent developments

10.8 Novo Nordisk A/S
10.8.1 Company details 
10.8.2 Financial outlook
10.8.3 Product summary 
10.8.4 Recent developments

10.9 Sanofi S.A.
10.9.1 Company details 
10.9.2 Financial outlook
10.9.3 Product summary 
10.9.4 Recent developments

10.10 Wockhardt Ltd.
10.10.1 Company details 
10.10.2 Financial outlook
10.10.3 Product summary 
10.10.4 Recent developments

SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.

The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings.  The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.

SPER-Methodology-1

SPER-Methodology-2

SPER-Methodology-3


Frequently Asked Questions About This Report
The Rapid Acting Insulin Market is projected to reach USD 11.85 billion by 2030, growing at a CAGR of 4.9% during the forecast period.
The North America region is anticipated to have the highest market share in the Rapid Acting Insulin Market.
The key players in the market include Companies Covered Adocia, Biocon Limited, Eli Lilly, Gan & Lee Pharmaceuticals Co. Ltd., Geropharm, MannKind Corporation, Merck & Co. Inc., Novo Nordisk A/S, Sanofi S.A., Wockhardt Ltd.
The Rapid Acting Insulin Market size is USD 11.85 billion from 2022 to 2030.
The Rapid Acting Insulin Market segment is Covered By Product, By Indication, By Distribution Channel.
The Rapid Acting Insulin Market grew in market size from 2021. The Market is expected to reach USD 11.85 billion by 2030, at a CAGR of 4.9% during the forecast period.
The Rapid Acting Insulin Market CAGR of 4.9% during the forecast period.
You can get the sample pages by clicking the link - Click Here
The rise in the global prevalence of diabetes is driving the global market for rapid acting insulin.
Not able to find what you are looking for? Need customization in the existing report?
Click Here
PLACE AN ORDER
  • 15% off
     
    $ 4250
  • 20% off
             
    $ 5650
  • 25% off
         
    $ 7450
Pre-Purchase Inquiry
SEND AN INQUIRY
NEED CUSTOMIZATION?
Request Customization
100% Secure Payment

SPER American Express
SPER VISA
SPER Master Card
SPER Mestro
SPER Paypal
SPER CCAvenues

Join SPER Panel

Our Global Clients

Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
SPER-Astellas Pharma
SPER-Citi Bank
SPER-Microsoft
SPER-EY
SPER-Sanofi
SPER-p&g
SPER-Johnson & Johnson
SPER-SIEMENS
SPER-LOREAL
SPER-Pfizer
SPER-IPSOS
SPER-Heineken
SPER-IQVIA
SPER-Kankar IMRB
SPER-Astellas Pharma
SPER-Citi Bank
SPER-Microsoft
SPER-EY
SPER-Sanofi
SPER-p&g
SPER-Johnson & Johnson
SPER-SIEMENS
SPER-LOREAL
SPER-Pfizer
SPER-IPSOS
SPER-Heineken
SPER-IQVIA
SPER-Kankar IMRB

SPER

Market Research

We are the leading, full-service global market research and consulting company.

Certificates
iso-1 iso-1
Secure Payments
SPER Payment Options
Connect with us